Skip to content

Tranexamic Acid in Total Knee Replacement

Multiple Intravenous Tranexamic Acid Doses Can Reduce Postoperative Blood Loss and Improve the Functional Outcome in Total Knee Arthroplasty Without Tourniquet: a Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03656445
Enrollment
180
Registered
2018-09-04
Start date
2015-10-01
Completion date
2017-03-31
Last updated
2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis Knee

Keywords

total knee arthroplasty, tranexamic acid, without tourniquet, blood loss, function, multiple doses

Brief summary

Multiple intravenous Tranexamic Acid doses can reduce postoperative blood loss and improve the functional outcome in total knee arthroplasty without tourniquet: a randomized controlled study.

Detailed description

A total of 180 patients undergoing TKA for knee osteoarthritis were stratified in three equal groups. All surgeries were performed under spinal anesthesia, without tourniquet and patients should be in agreement with the established inclusion/exclusion criteria. Group A (60 patients) received 1g of IV TXA, Group B (60 patients) received an additional dose of IV TXA and Group C (60 patients) received three doses of IV TXA. The measured outcomes were the Hemoglobin (Hb) decrease, the transfusion rate, the functional, quality of life (QoL) and pain assessment based on their corresponding scoring system.

Interventions

DRUGTranexamic Acid

1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia

Sponsors

Democritus University of Thrace
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. varus deformity less than 10o 2. lack of extension not more than 10o 3. flexion of at least 90o.

Exclusion criteria

1. uncontrolled medical diseases/comorbidities 2. allergy and/or hypersensitivity to TXA 3. a known history of thromboembolic disease, cardiovascular disease 4. coronary or vascular stent placed within the past 12 months 5. cerebral vascular disease (a history of stroke) 6. subarachnoid hemorrhage 7. preoperative coagulopathy (a platelet \[PLT\] count \<150,000/mm3 or an international normalized ratio greater than 1.5 8. preoperative renal or hepatic dysfunction 9. retinal vein or artery occlusion 10. patients with anemia (\<12 g/dL for female, \<13 g/dL for male)

Design outcomes

Primary

MeasureTime frameDescription
Need for trasfussion24 hoursTransfussion rate/quantity in 1st post-op day
hemoglobin change1st,2nd and 4th post-operative dayHemoglobin decrease/change during the four post-operative days
Blood loss24 hourscalculated total blood loss (TBL) the 1st post-op day
Platelet count change24 hours, 48 hours, 96 hoursPlatelet count increase/decrease/change during the 1st,2nd and 4th day

Secondary

MeasureTime frameDescription
Knee Society Score (KSS) KSS2nd and 4th post op days + 6th week and 12th weekChange in this Score which is an objective scoring system to rate the knee and patient's functional abilities such as walking and stair climbing before and after TKA. Maximum score is 100 (best functionality) and lowest score is 0 (worst functionality)
Function Knee Society Score2nd and 4th post op days + 6th week and 12th weekChange in this score which utilizes walking distance and stair climbing as the main parameters, with deduction for the use of a walking aid. Maximum score is 100 (best functionality) and lowest score is 0 (worst functionality)
EuroQol2nd and 4th post op days + 6th week and 12th weekChanges in this score which is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. Crosswalk value sets for the EQ-5D-5L has been used to asses the results into numbers. Maximum score is 1 (which means best quality of life) and the lowest is -0.594(which means the worst quality of life)
VAS pain (analogue pain scale)2nd and 4th post op days + 6th week and 12th weekThe pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. For pain intensity, the scale is most commonly anchored by no pain (score of 0) and pain as bad as it could be or worst imaginable pain (score of 10 \[100-mm scale\])

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026